Ives Jeffrey L. 4

4 · Acumen Pharmaceuticals, Inc. · Filed Jun 5, 2026

AI-generated summary of this filing

Updated Jun 5, 2026

Acumen (ABOS) Director Jeffrey Ives Receives RSU/Derivative Award

What Happened

Jeffrey L. Ives, a director of Acumen Pharmaceuticals (ABOS), received two equity awards on 2026-06-03: 35,500 restricted stock units (RSUs) and a 53,250-share derivative award. Both were granted at $0.00 (standard for compensation awards) and are contingent on future vesting rather than being immediately owned shares.

Key Details

Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely).
Grants: 35,500 RSUs (footnote F1) and 53,250 derivative shares/option-like award (footnote F2); grant price reported $0.00; total immediate cash value reported $0.
Vesting: Both awards vest in full on the earlier of the first anniversary of the grant or the 2027 annual meeting, subject to continuous service through the vesting date (per F1 and F2).
Shares owned after transaction: Not specified in the filing.
Filing timeliness: Appears timely (filed two days after the transaction); no 10b5-1, tax-withholding, or late-filing notes in the provided data.

Context

RSUs and derivative awards are compensation grants that convert into actual shares only if and when they vest; they are not open-market purchases or immediate sales. Such awards are common for board compensation and do not, by themselves, indicate the insider bought or sold stock in the market.

Form 4

Period: 2026-06-03

Director

Transactions

Award
Common Stock
[F1]
2026-06-03+35,500→ 48,300 total
Award
Stock Option (right to buy)
[F2]
2026-06-03+53,250→ 53,250 total
Exercise: $2.29Exp: 2036-06-03→ Common Stock (53,250 underlying)

Footnotes (2)

[F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
[F2]The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Signature

/s/ Derek Meisner, Attorney-in-Fact|2026-06-05

1 file